Evidence map›Paper›PMID 38716733›Full record

Trial reportJCI insight2024

Immune responses associated with protection induced by chemoattenuated PfSPZ vaccine in malaria-naive Europeans.

Yoanne D Mouwenda, Simon P Jochems, Vincent Van Unen, Madeleine Eunice Betouke Ongwe, Wouter A A de Steenhuijsen Piters, Koen A Stam, Marguerite Massinga Loembe, Betty Kim Lee Sim, Meral Esen, Stephen L Hoffman and 4 more

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in JCI insight, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Malaria: past, present, and future.Signal transduction and targeted therapy · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Yoanne D MouwendaCentre de Recherches Médicales de Lambaréné, Lambaréné, Gabon.
Simon P JochemsDepartment of Parasitology, Leiden University Medical Center (LUMC), Leiden, Netherlands.
Vincent Van UnenDepartment of Immunology, Leiden University Medical Center, Leiden, Netherlands.
Madeleine Eunice Betouke OngweCentre de Recherches Médicales de Lambaréné, Lambaréné, Gabon.
Wouter A A de Steenhuijsen PitersDepartment of Parasitology, Leiden University Medical Center (LUMC), Leiden, Netherlands.
Koen A StamDepartment of Parasitology, Leiden University Medical Center (LUMC), Leiden, Netherlands.
Marguerite Massinga LoembeAfrica Society of Laboratory Medicine, Headquarters, Johannesburg, South Africa.
Betty Kim Lee SimSanaria Inc., Rockville, Maryland, USA.
Meral EsenCentre de Recherches Médicales de Lambaréné, Lambaréné, Gabon.
Stephen L HoffmanSanaria Inc., Rockville, Maryland, USA.
Peter G KremsnerCentre de Recherches Médicales de Lambaréné, Lambaréné, Gabon.
Rolf FendelCentre de Recherches Médicales de Lambaréné, Lambaréné, Gabon.
Benjamin MordmüllerCentre de Recherches Médicales de Lambaréné, Lambaréné, Gabon.
Maria YazdanbakhshDepartment of Parasitology, Leiden University Medical Center (LUMC), Leiden, Netherlands.

Funding

Plasmodium Falciparum Whole Sporozoite Malaria VaccineR44AI055229 · NIAID · SANARIA, INC. · PI HOFFMAN, STEPHEN LEV · 2005 to 2015
$10.0M
Universal Attenuated Sporozoite Vaccine and Challenge SystemR44AI058375 · NIAID · SANARIA, INC. · PI HOFFMAN, STEPHEN LEV · 2006 to 2018
$9.9M
Baseline host and environmental factors that impact pre-erythrocytic malaria vaccine (hypo)responsiveness in endemic regionsU01AI165745 · NIAID · LEIDEN UNIVERSITY MEDICAL CENTER · PI Maria Yazdanbakhsh · 2022 to 2026
$3.3M
NIAID NIH HHS R44 AI055229NIAID NIH HHS R44 AI058375NIAID NIH HHS U01 AI165745
6 · The paper itself

Abstract

Vaccination of malaria-naive volunteers with a high dose of Plasmodium falciparum sporozoites chemoattenuated by chloroquine (CQ) (PfSPZ-CVac [CQ]) has previously demonstrated full protection against controlled human malaria infection (CHMI). However, lower doses of PfSPZ-CVac [CQ] resulted in incomplete protection. This provides the opportunity to understand the immune mechanisms needed for better vaccine-induced protection by comparing individuals who were protected with those not protected. Using mass cytometry, we characterized immune cell composition and responses of malaria-naive European volunteers who received either lower doses of PfSPZ-CVac [CQ], resulting in 50% protection irrespective of the dose, or a placebo vaccination, with everyone becoming infected following CHMI. Clusters of CD4+ and γδ T cells associated with protection were identified, consistent with their known role in malaria immunity. Additionally, EMRA CD8+ T cells and CD56+CD8+ T cell clusters were associated with protection. In a cohort from a malaria-endemic area in Gabon, these CD8+ T cell clusters were also associated with parasitemia control in individuals with lifelong exposure to malaria. Upon stimulation with P. falciparum-infected erythrocytes, CD4+, γδ, and EMRA CD8+ T cells produced IFN-γ and/or TNF, indicating their ability to mediate responses that eliminate malaria parasites.

Indexed as

CD4-Positive T-LymphocytesCD8-Positive T-LymphocytesMalaria, FalciparumMalaria VaccinesPlasmodium falciparumSporozoitesAdolescentAdultAntimalarialsCentral African PeopleChloroquineEuropeEuropean PeopleFemaleGabonHumansAntimalarialsChloroquineMalaria VaccinesVaccines, AttenuatedCellular immune responseCytokinesImmunologyMalariaVaccines

Identifiers

PMID38716733
PMCPMC11141902

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.